SEGMENT REPORTING

12 Months Ended

Dec. 31, 2025

Disclosure of operating segments [abstract]

NOTE 19 – SEGMENT REPORTING

The Company operates in a single reportable operating segment – the development and commercialization of therapeutics. Its corporate headquarters and development activities are in Israel, while its revenues stem from activities carried out in the U.S. and Asia (primarily Greater China). In this regard, product sales relate to the Company’s direct commercialization activities in the U.S. from October 2023 through November 2024, while license revenues relate to outlicensing agreements entered into in Asia and in the U.S. in October 2023 and November 2024, respectively. Set forth below is a breakdown of revenues from external parties by geographic region.

	Year ended December 31,
	2023		2024		2025
	in USD thousands
China		4,610		14,957		-
U.S.		190		13,983		1,180
		4,800		28,940		1,180

Substantially all of the Company’s non-current assets are located in Israel. See Notes 15 and 16 for information on customers representing 10% or more of total revenues.